[1] |
WAN J, QIN Z, LEI H, et al. Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance[J]. Pharmacol Res,2020,161:105118. doi: 10.1016/j.phrs.2020.105118 |
[2] |
王佩. 大环内酯类抗生素的心脏毒性[J]. 药物不良反应杂志, 2000, 2(2):80-83. doi: 10.3760/j.issn.1008-5734.2000.02.003 |
[3] |
ABBOTT G W, SESTI F, SPLAWSKI I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia[J]. Cell,1999,97(2):175-187. doi: 10.1016/S0092-8674(00)80728-X |
[4] |
SMITH P L, BAUKROWITZT, YELLEN G. The inward rectification mechanism of the HERG cardiac potassium channel[J]. Nature,1996,379(6568):833-836. doi: 10.1038/379833a0 |
[5] |
JO S H, HONG H K, JUNG S J, et al. Maprotiline block of the human ether-a-go-go-related gene (HERG) K^+ channel[J]. Arch Pharmacal Res,2007,30(4):453-460. doi: 10.1007/BF02980219 |
[6] |
EAP C B, CRETTOL S, ROUGIER J S, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers[J]. Clin Pharmacol Ther,2007,81(5):719-728. doi: 10.1038/sj.clpt.6100120 |
[7] |
王玉珠. 新药临床试验前安全药理学研究的发展过程[J]. 中国临床药理学杂志, 2011, 27(7):557-560. doi: 10.3969/j.issn.1001-6821.2011.07.012 |
[8] |
李波. 安全药理学的快速发展对创新药物研发作用巨大[J]. 中国药理学与毒理学杂志, 2015, 29(5):720-721. doi: 10.3867/j.issn.1000-3002.2015.05.034 |
[9] |
李波. 安全药理学的国内外发展概况[J]. 中国新药杂志, 2004, 13(11):694-698. |
[10] |
夏静. 应用膜片钳技术检测药物对HERG通道抑制作用的实验过程及要点[J]. 军事医学, 2015, 11:884-886. |
[11] |
李春. 人胚肾(HEK293)细胞自身的钾通道[J]. 中国血液净化, 2007, 6(11):604-607. doi: 10.3969/j.issn.1671-4091.2007.11.008 |
[12] |
MOHAMMAD S, ZHOU Z, GONG Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride[J]. Am J Physiol,1997,273(5):H2534-H2538. |
[13] |
元沙沙. 胃肠动力药西沙比利对表达于HEK293细胞的人ether-a-go-go相关基因2通道的影响[J]. 首都医科大学学报, 2014, 35(6):670-674. |
[14] |
ROCHE O, TRUBE G, ZUEGGE J, et al. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries[J]. Chembiochem,2002,3(5):455-459. doi: 10.1002/1439-7633(20020503)3:5<455::AID-CBIC455>3.0.CO;2-L |
[15] |
REDFERN W S, CARLSSON L, DAVIS A S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development[J]. Cardiovasc Res,2003,58(1):32-45. doi: 10.1016/S0008-6363(02)00846-5 |
[16] |
CAVERO I, MESTRE M, GUILLON J M, et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias[J]. Expert Opin Pharmacother,2000,1(5):947-973. doi: 10.1517/14656566.1.5.947 |
[17] |
WEBSTER R, LEISHMAN D, WALKER D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes[J]. Curr Opin Drug Discov Devel,2002,5(1):116-126. |
[18] |
梁永志. 大环内酯类抗生素心脏毒性防治[J]. 中国实用医药, 2008, 3(5):49-50. doi: 10.3969/j.issn.1673-7555.2008.05.029 |
[19] |
伦新强. 大环内酯类抗生素心脏毒性防治[J]. 中国药物应用与监测, 2005, 2(3):28-29. doi: 10.3969/j.issn.1672-8157.2005.03.010 |